Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone303-703-4906
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.43 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Zynex (OTCMKTS:ZYXI) Frequently Asked Questions
What is Zynex's stock symbol?
Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."
How were Zynex's earnings last quarter?
Zynex Inc. (OTCMKTS:ZYXI) released its earnings results on Tuesday, February, 26th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $9.34 million for the quarter, compared to analyst estimates of $8.82 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. View Zynex's Earnings History.
What guidance has Zynex issued on next quarter's earnings?
Zynex issued an update on its first quarter 2019 earnings guidance on Tuesday, February, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.3-8.8 million, compared to the consensus revenue estimate of $8.07 million.
What price target have analysts set for ZYXI?
1 analysts have issued 12-month target prices for Zynex's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Zynex's stock price to reach $7.00 in the next year. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Zynex.
What is the consensus analysts' recommendation for Zynex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.
Has Zynex been receiving favorable news coverage?
News articles about ZYXI stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynex earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the near future.
Who are some of Zynex's key competitors?
Some companies that are related to Zynex include Viewray (VRAY), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Cutera (CUTR), Electrocore (ECOR), Edap Tms (EDAP), BioSig Technologies (BSGM), Fonar (FONR), Second Sight Medical Products (EYES), Stereotaxis (STXS), IRIDEX (IRIX), Helius Medical Technologies (HSDT), Soleno Therapeutics (SLNO) and Viveve Medical (VIVE).
What other stocks do shareholders of Zynex own?
Who are Zynex's key executives?
Zynex's management team includes the folowing people:
- Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
- Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
- Mr. David B. Mogill, VP of Operations
- Mr. Robert Bird, VP of Marketing
- Mr. Steve Siefring, Director of Bus. Devel.
How do I buy shares of Zynex?
Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zynex's stock price today?
One share of ZYXI stock can currently be purchased for approximately $5.28.
How big of a company is Zynex?
Zynex has a market capitalization of $170.22 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis.
What is Zynex's official website?
How can I contact Zynex?
Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]
MarketBeat Community Rating for Zynex (OTCMKTS ZYXI)
MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote "Outperform" if you believe ZYXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
